Objective: Studies in recent times researching the correlation between serum endotrophin level and Type 2 DM have focused on the association of fatty liver with metabolic syndrome. This study aims to research the correlation between serum endotrophin levels, defined as a marker of metabolic dysregulation, with nonalcoholic fatty liver in metabolic syndrome patients, with increasing prevalence. Methods: Our prospective study included 40 patients (24 females and 16 males) with metabolic syndrome attending the internal medicine clinic and 20 healthy volunteers (ten females and ten males). Evaluation of patients in terms of liver steatosis used transabdominal ultrasonography with a Toshiba 500 Aplio brand model ultrasound device with 10 MHz convex probe with transient elastography method. Fatty Liver Index and Hepatic Steatosis Index (HSI) were calculated on the basis sample analyses. The endotrophin levels were studied with a Sunred enzyme-linked ımmunosorbent assay kit. Results: Endotrophin levels were found to be lower in the group with metabolic syndrome compared to the healthy group and results were statistically significant different (p
1. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640–5.
2. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95.
3. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–50.
4. Williams SC. Link between obesity and cancer. Proceedings of the National Academy of Sciences 2013;110:8753–4.
5. Sun K, Park J, Kim M, Scherer PE. Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARg agonist treatment. Diabetologia 2017;60:24–9.
6. Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun 2014;5:3485.
7. Karsdal MA, Henriksen K, Genovese F, Leeming DJ, Nielsen MJ, Riis BJ, et al. Serum endotrophin identifies optimal responders to PPARg agonists in type 2 diabetes. Diabetologia 2017;60:50–9.
8. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775–7.
9. Cantero I, Elorz M, Abete I, Marin BA, Herrero JI, Monreal JI, et al. Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults. Int J Med Sci 2019;16:75–83.
10. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol and Hepatol 2007;5:1214–20.
11. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clinic Invest 2011;121:2094–101.
12. Sun K, Tordjman J, Clément K, Scherer PE. Fibrosis and adipose tissue dysfunction. Cell Metab 2013;18:470–7.
13. Kusminski, Christine M, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis 2009;14:1484–95.
14. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010;21:345– 52.
15. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503–8.
16. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
17. Polyzos, Stergios A, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones 2014;13:519–31.
18. Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest 2012;122:4243–56.
19. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009;29:1575–91.
20. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454– 62.
21. Srinivasa Babu A, Wells ML, Teytelboym OM, Mackey JE, Miller FH, Yeh BM, et al. Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. Radiographics 2016;36:1987–2006.